Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Syngenta India's emamectin under irregularity review

The Indian Central Insecticides Board’s Registration Committee has issued a notice to Syngenta India for irregularities related to the import of the insecticide, emamectin benzoate. The issue refers to the import of a 5% soluble granule formulation in 2007, when the company did not have the requisite approval to do so. The import was done on the basis of a certificate of registration that was meant for domestic manufacture and was also expired at that time. Different batches repacked at the company’s facility at Goa were given different dates of manufacture and expiry “by giving manufacturing dates as the dates on which imported material was repacked in the country”. Syngenta has been asked to submit a reply within 15 days stating why its approval for the ai may not be withdrawn and cancelled, and “other necessary actions, as deemed fit, be initiated under the provisions of Insecticides Act 1968 and Insecticides Rules 1971”.

Topics

What to read next

UsernamePublicRestriction

Register

AG004487

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel